title: Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.
abstract: Individuals infected with human immunodeficiency virus (HIV) have excess risk of developing human papillomavirus (HPV)-related disease. A substantial fraction of HPV-associated cancers is caused by HPV serotypes not included in the currently available vaccines. Among healthy women, both Cervarix(®) (HPV-16/18, GlaxoSmithKline Biologicals, GSK) and Gardasil(®) (HPV-6/11/16/18, Merck) have demonstrated partial cross-protection against certain oncogenic non-vaccine HPV-types. Currently, there are no available data on vaccine-induced cross-protection in men and little is known about cross-reactive immunity after HPV-vaccination of HIV-infected individuals. In an investigator-initiated trial, we randomized 91 HIV-positive men and women to receive vaccination with Cervarix(®) or Gardasil(®). The HPV-DNA status of the participants was determined with pcr before and after immunization. Cross-reactive antibody responses against HPV-31, HPV-33, and HPV-45 were evaluated for up to 12 months using a pseudovirion-based neutralization assay (PBNA). Geometric mean antibody titers (GMTs) were compared among vaccine groups and genders at 7 and 12 months.: Both vaccines induced anti-HPV-31, -33, and -45 neutralizing antibodies in participants who were seronegative and HPV-DNA negative for those types at study entry. Geometric mean antibody titers were comparable between vaccine groups. Interestingly, anti-HPV-31 and -33 antibody titers were higher among women compared with men at 7 and 12 months.: In conclusion, both licensed HPV-vaccines induced cross-neutralizing antibodies against frequent oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults, and women had greater serological responses against HPV-31 and -33 compared with men.
authors.affiliation: Department of Infectious Diseases; Aarhus University Hospital; Aarhus, Denmark.
authors.forename: Lars
authors.initials: L
authors.lastname: Toft
authors.affiliation: Department of Infectious Diseases; Aarhus University Hospital; Aarhus, Denmark.
authors.forename: Martin
authors.initials: M
authors.lastname: Tolstrup
authors.affiliation: Research Program Infection and Cancer; German Cancer Research Center; Heidelberg, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Müller
authors.affiliation: Chemical Biology Core Facility; European Molecular Biology Laboratory; Heidelberg, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Sehr
authors.affiliation: Department of Pathology; Copenhagen University Hospital; Hvidovre, Denmark; Clinical Research Centre; Copenhagen University Hospital; Hvidovre, Denmark.
authors.forename: Jesper
authors.initials: J
authors.lastname: Bonde
authors.affiliation: Department of Infectious Diseases; Aarhus University Hospital; Aarhus, Denmark.
authors.forename: Merete
authors.initials: M
authors.lastname: Storgaard
authors.affiliation: Department of Infectious Diseases; Aarhus University Hospital; Aarhus, Denmark.
authors.forename: Lars
authors.initials: L
authors.lastname: Østergaard
authors.affiliation: Department of Infectious Diseases; Aarhus University Hospital; Aarhus, Denmark.
authors.forename: Ole S
authors.initials: OS
authors.lastname: Søgaard
mesh_terms: D000328:Adult; D052685:Alphapapillomavirus / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D058952:Human papillomavirus 31 / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D006801:Humans; D055261:Immunogenetic Phenomena / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D008297:Male; D030361:Papillomavirus Infections / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D012703:Serotyping
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18
keywords: Cervarix; Gardasil; HPV vaccines; cross neutralization; neutralizing antibodies; serology